Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Transl Med ; 16(754): eadi6887, 2024 Jul 03.
Article in English | MEDLINE | ID: mdl-38959328

ABSTRACT

Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2-infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.


Subject(s)
COVID-19 , Class Ib Phosphatidylinositol 3-Kinase , Inflammation , SARS-CoV-2 , COVID-19/pathology , Class Ib Phosphatidylinositol 3-Kinase/metabolism , Animals , Inflammation/pathology , Humans , COVID-19 Drug Treatment , Methicillin-Resistant Staphylococcus aureus/drug effects , Mice , Lung/pathology , Phosphoinositide-3 Kinase Inhibitors/pharmacology , Phosphoinositide-3 Kinase Inhibitors/therapeutic use , Cytokine Release Syndrome/drug therapy , Capillary Permeability/drug effects , Mice, Inbred C57BL , Staphylococcal Infections/drug therapy , Staphylococcal Infections/pathology
2.
Dis Model Mech ; 14(8)2021 08 01.
Article in English | MEDLINE | ID: mdl-34407185

ABSTRACT

There is an urgent need for accurate, scalable and cost-efficient models of the tumor microenvironment. Here, we detail how to fabricate and use the metabolic microenvironment chamber (MEMIC) - a 3D-printed ex vivo model of intratumoral heterogeneity. A major driver of the cellular and molecular diversity in tumors is accessibility to the blood stream. Whereas perivascular tumor cells have direct access to oxygen and nutrients, cells further from the vasculature must survive under progressively more ischemic environments. The MEMIC simulates this differential access to nutrients, allow co-culturing any number of cell types, and it is optimized for live imaging and other microscopy-based analyses. Owing to a modular design and full experimental control, the MEMIC provides insights into the tumor microenvironment that would be difficult to obtain via other methods. As proof of principle, we show that cells sense gradual changes in metabolite concentration leading to predictable molecular and cellular spatial patterns. We propose the MEMIC as a complement to standard in vitro and in vivo experiments, diversifying the tools available to accurately model, perturb and monitor the tumor microenvironment.


Subject(s)
Neoplasms , Tumor Microenvironment , Coculture Techniques , Humans , Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...